Effective June 1, 2016, the Nova Scotia Pharmacare will begin funding INFLECTRA™ (infliximab) as an exception status benefit. For infliximab-naïve ... Read More
Events
25
May2016
18
May2016
The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update
/ News, pCPA, What's New
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016:
23 ... Read More
17
May2016
CADTH Releases Recommendations Report for Anti-Vascular Endothelial Growth Factor Drugs for Retinal Conditions
/ CADTH, News, What's New
On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its ... Read More
03
May2016
The Patented Medicine Prices Review Board (PMPRB) has released its April 2016 NEWSletter. Some recent changes include:
Public Consultation on PMPRB ... Read More
03
May2016
In June/July 2015, PDCI Market Access and H3 Consulting conducted an on-line survey to gauge the interest, experience and expectation ... Read More
22
Apr2016
To meet the needs of Quebec’s Ministry of Health and Social Services (MSSS), the Institut national d’excellence en santé et ... Read More
19
Apr2016
The pan-Canadian Pharmaceutical Alliance (pCPA) Releases its April 1st, 2016 Update
/ pCPA, What's New
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide ... Read More
11
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics ... Read More